Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Blood biomarker panel recommended for personalized prediction, prognosis, and prevention of complications associated with abdominal aortic aneurysm

J. Molacek, V. Treska, J. Zeithaml, I. Hollan, O. Topolcan, L. Pecen, D. Slouka, M. Karlikova, R. Kucera,

. 2019 ; 10 (2) : 125-135. [pub] 20190603

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19036000

Grantová podpora
NV15-32727A MZ0 CEP - Centrální evidence projektů

The aim of the study was to evaluate the ability of following biomarkers as diagnostic tools and risk predictors of AAA: C-reactive protein, interleukin-6, pentraxin-3, galectin-3, procollagen type III N-terminal peptide, C-terminal telopeptide of type I collagen, high-sensitive troponin I, and brain natriuretic peptide. Seventy-two patients with an AAA and 100 healthy individuals were enrolled into the study. We assessed individual biomarker performance and correlation between the AAA diameter and biomarker levels, and also, a multivariate logistic regression was used to design a possible predictive model of AAA growth and rupture risk. We identified following four parameters with the highest potential to find a useful place in AAA diagnostics: galectin-3, pentraxin-3, interleukin-6, and C-terminal telopeptide of type I. The best biomarkers in our evaluation (galectin-3 and pentraxin-3) were AAA diameter-independent. With the high AUC and AAA diameter correlation, the high-sensitive troponin I can be used as an independent prognostic biomarker of the upcoming heart complications in AAA patients. Authors recommend to add biomarkers as additional parameters to the current AAA patient management. Main addition value of biomarkers is in the assessment of the AAA with the smaller diameter. Elevated biomarkers can change the treatment decision, which would be done only based on AAA diameter size. The best way how to manage the AAA patients is to create a reliable predictive model of AAA growth and rupture risk. A created multiparameter model gives very promising results with the significantly higher efficiency compared with the use of the individual biomarkers.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19036000
003      
CZ-PrNML
005      
20201109151211.0
007      
ta
008      
191007s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s13167-019-00173-2 $2 doi
035    __
$a (PubMed)31258818
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Molacek, Jiri $u 1Department of Surgery, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
245    10
$a Blood biomarker panel recommended for personalized prediction, prognosis, and prevention of complications associated with abdominal aortic aneurysm / $c J. Molacek, V. Treska, J. Zeithaml, I. Hollan, O. Topolcan, L. Pecen, D. Slouka, M. Karlikova, R. Kucera,
520    9_
$a The aim of the study was to evaluate the ability of following biomarkers as diagnostic tools and risk predictors of AAA: C-reactive protein, interleukin-6, pentraxin-3, galectin-3, procollagen type III N-terminal peptide, C-terminal telopeptide of type I collagen, high-sensitive troponin I, and brain natriuretic peptide. Seventy-two patients with an AAA and 100 healthy individuals were enrolled into the study. We assessed individual biomarker performance and correlation between the AAA diameter and biomarker levels, and also, a multivariate logistic regression was used to design a possible predictive model of AAA growth and rupture risk. We identified following four parameters with the highest potential to find a useful place in AAA diagnostics: galectin-3, pentraxin-3, interleukin-6, and C-terminal telopeptide of type I. The best biomarkers in our evaluation (galectin-3 and pentraxin-3) were AAA diameter-independent. With the high AUC and AAA diameter correlation, the high-sensitive troponin I can be used as an independent prognostic biomarker of the upcoming heart complications in AAA patients. Authors recommend to add biomarkers as additional parameters to the current AAA patient management. Main addition value of biomarkers is in the assessment of the AAA with the smaller diameter. Elevated biomarkers can change the treatment decision, which would be done only based on AAA diameter size. The best way how to manage the AAA patients is to create a reliable predictive model of AAA growth and rupture risk. A created multiparameter model gives very promising results with the significantly higher efficiency compared with the use of the individual biomarkers.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Treska, Vladislav $u 1Department of Surgery, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
700    1_
$a Zeithaml, Jan $u 1Department of Surgery, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
700    1_
$a Hollan, Ivana $u 2Department of Rheumatology, Hospital for Rheumatic Diseases, 2609 Lillehammer, Norway. 3Department of Research, Innlandet Hospital Trust, Brumunddal, Norway. 4Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA USA.
700    1_
$a Topolcan, Ondrej $u 5Department of Immunochemistry Diagnostics, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
700    1_
$a Pecen, Ladislav $u 5Department of Immunochemistry Diagnostics, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
700    1_
$a Slouka, David $u 5Department of Immunochemistry Diagnostics, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
700    1_
$a Karlikova, Marie $u 5Department of Immunochemistry Diagnostics, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic.
700    1_
$a Kucera, Radek $u 5Department of Immunochemistry Diagnostics, University Hospital and Faculty of Medicine in Pilsen, Pilsen, Czech Republic. 6Department of Immunochemistry Diagnostics, University Hospital Pilsen, Dr. E. Benese 1128/13, 305 99 Pilsen, Czech Republic.
773    0_
$w MED00181668 $t The EPMA journal $x 1878-5077 $g Roč. 10, č. 2 (2019), s. 125-135
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31258818 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20201109151210 $b ABA008
999    __
$a ind $b bmc $g 1452660 $s 1074550
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 10 $c 2 $d 125-135 $e 20190603 $i 1878-5077 $m The EPMA journal $n EPMA J $x MED00181668
GRA    __
$a NV15-32727A $p MZ0
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...